Does the media favor AMRX or HROW?

In the previous week, Harrow had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for Harrow and 10 mentions for Amneal Pharmaceuticals. Harrow's average media sentiment score of 0.96 beat Amneal Pharmaceuticals' score of 0.46 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DFTX or HROW?

In the previous week, Harrow had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 13 mentions for Harrow and 12 mentions for Definium Therapeutics. Harrow's average media sentiment score of 0.96 beat Definium Therapeutics' score of 0.41 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Harrow 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, HROW or INDV?

Indivior has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $275.59M 4.69 -$5.14M -$1.00 N/A Indivior $1.33B 3.06 $210M $2.79 12.36

Is HROW or INDV more profitable?

Indivior has a net margin of 26.65% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -13.51% -38.00% -3.37% Indivior 26.65% -283.11% 36.85%

Does the media prefer HROW or INDV?

In the previous week, Harrow had 8 more articles in the media than Indivior. MarketBeat recorded 13 mentions for Harrow and 5 mentions for Indivior. Indivior's average media sentiment score of 1.81 beat Harrow's score of 0.96 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MANE or HROW more profitable?

Veradermics has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Veradermics' return on equity of 0.00% beat Harrow's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Harrow -13.51% -38.00% -3.37%

Does the media refer more to MANE or HROW?

In the previous week, Harrow had 11 more articles in the media than Veradermics. MarketBeat recorded 13 mentions for Harrow and 2 mentions for Veradermics. Veradermics' average media sentiment score of 1.58 beat Harrow's score of 0.96 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Harrow 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TARS or HROW?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Harrow. MarketBeat recorded 16 mentions for Tarsus Pharmaceuticals and 13 mentions for Harrow. Harrow's average media sentiment score of 0.96 beat Tarsus Pharmaceuticals' score of 0.63 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harrow (HROW) Competitors

$34.48 -2.10 (-5.74%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$34.94 +0.46 (+1.33%)

As of 09/11/2026 07:41 PM Eastern

Compare

HROW vs. AMRX, DFTX, INDV, MANE, and TARS

Should you buy Harrow stock or one of its competitors? Harrow's main competitors and comparable companies include Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Indivior (INDV), Veradermics (MANE), and Tarsus Pharmaceuticals (TARS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Harrow compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Harrow had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for Harrow and 10 mentions for Amneal Pharmaceuticals. Harrow's average media sentiment score of 0.96 beat Amneal Pharmaceuticals' score of 0.46 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.80	$72.06M	$0.49	34.71
Harrow	$275.59M	4.69	-$5.14M	-$1.00	N/A

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Harrow	-13.51%	-38.00%	-3.37%

Amneal Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Harrow has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Amneal Pharmaceuticals presently has a consensus target price of $19.57, indicating a potential upside of 15.06%. Harrow has a consensus target price of $66.38, indicating a potential upside of 92.50%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Harrow	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Amneal Pharmaceuticals beats Harrow on 9 of the 16 factors compared between the two stocks.

How does Harrow compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Harrow has higher revenue and earnings than Definium Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Harrow	$275.59M	4.69	-$5.14M	-$1.00	N/A

Definium Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Harrow	-13.51%	-38.00%	-3.37%

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Definium Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 62.00%. Harrow has a consensus target price of $66.38, suggesting a potential upside of 92.50%. Given Harrow's higher probable upside, analysts clearly believe Harrow is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harrow	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Harrow had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 13 mentions for Harrow and 12 mentions for Definium Therapeutics. Harrow's average media sentiment score of 0.96 beat Definium Therapeutics' score of 0.41 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Harrow	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Harrow has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

Harrow beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Harrow compare to Indivior?

Harrow (NASDAQ:HROW) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Indivior has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$275.59M	4.69	-$5.14M	-$1.00	N/A
Indivior	$1.33B	3.06	$210M	$2.79	12.36

Indivior has a net margin of 26.65% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Indivior	26.65%	-283.11%	36.85%

Harrow currently has a consensus price target of $66.38, indicating a potential upside of 92.50%. Indivior has a consensus price target of $45.17, indicating a potential upside of 30.96%. Given Harrow's higher possible upside, equities research analysts clearly believe Harrow is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

72.8% of Harrow shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Harrow had 8 more articles in the media than Indivior. MarketBeat recorded 13 mentions for Harrow and 5 mentions for Indivior. Indivior's average media sentiment score of 1.81 beat Harrow's score of 0.96 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Harrow has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Indivior has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Summary

Indivior beats Harrow on 9 of the 16 factors compared between the two stocks.

How does Harrow compare to Veradermics?

Veradermics (NYSE:MANE) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

72.8% of Harrow shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Harrow had 11 more articles in the media than Veradermics. MarketBeat recorded 13 mentions for Harrow and 2 mentions for Veradermics. Veradermics' average media sentiment score of 1.58 beat Harrow's score of 0.96 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Harrow	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics presently has a consensus target price of $153.00, indicating a potential upside of 54.23%. Harrow has a consensus target price of $66.38, indicating a potential upside of 92.50%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Harrow	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Harrow has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Harrow	$275.59M	4.69	-$5.14M	-$1.00	N/A

Veradermics has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Veradermics' return on equity of 0.00% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Harrow	-13.51%	-38.00%	-3.37%

Summary

Harrow beats Veradermics on 9 of the 13 factors compared between the two stocks.

How does Harrow compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Tarsus Pharmaceuticals currently has a consensus price target of $92.57, indicating a potential upside of 16.72%. Harrow has a consensus price target of $66.38, indicating a potential upside of 92.50%. Given Harrow's higher possible upside, analysts clearly believe Harrow is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Harrow	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Harrow's net margin of -13.51%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Harrow	-13.51%	-38.00%	-3.37%

Tarsus Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Harrow has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Harrow. MarketBeat recorded 16 mentions for Tarsus Pharmaceuticals and 13 mentions for Harrow. Harrow's average media sentiment score of 0.96 beat Tarsus Pharmaceuticals' score of 0.63 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Harrow has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$606.33M	5.74	-$66.42M	-$1.09	N/A
Harrow	$275.59M	4.69	-$5.14M	-$1.00	N/A

Summary

Tarsus Pharmaceuticals beats Harrow on 9 of the 17 factors compared between the two stocks.

Get Harrow News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HROW vs. The Competition

Export

Metric	Harrow	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.37B	$12.44B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-34.48	799.75	275.24	25.29
Price / Sales	4.69	763.36	655.99	98.94
Price / Cash	42.32	89.25	77.04	51.44
Price / Book	24.45	10.39	10.33	6.20
Net Income	-$5.14M	$2.85B	$3.50B	$358.50M
7 Day Performance	-10.53%	-3.61%	-3.32%	-2.35%
1 Month Performance	-12.40%	0.86%	-0.41%	-2.77%
1 Year Performance	-12.53%	3.47%	19.21%	7.63%

Harrow Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HROW Harrow	2.5355 of 5 stars	$34.48 -5.7%	$66.38 +92.5%	-12.6%	$1.37B	$275.59M	N/A	373	News Coverage Positive News Analyst Forecast High Trading Volume
AMRX Amneal Pharmaceuticals	3.9796 of 5 stars	$17.44 flat	$19.00 +8.9%	+68.6%	$5.57B	$3.02B	35.59	8,500	Positive News Analyst Forecast
DFTX Definium Therapeutics	2.8238 of 5 stars	$38.09 flat	$63.00 +65.4%	+303.0%	$5.12B	N/A	N/A	40	Analyst Forecast
INDV Indivior	4.169 of 5 stars	$34.94 flat	$45.17 +29.3%	+44.4%	$4.12B	$1.24B	12.52	1,051	News Coverage Positive News
MANE Veradermics	2.7623 of 5 stars	$98.36 -0.2%	$153.00 +55.6%	N/A	$4.12B	N/A	N/A	19	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HROW) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow (HROW) Competitors

HROW vs. AMRX, DFTX, INDV, MANE, and TARS

How does Harrow compare to Amneal Pharmaceuticals?

Summary

How does Harrow compare to Definium Therapeutics?

Summary

How does Harrow compare to Indivior?

Summary

How does Harrow compare to Veradermics?

Summary

How does Harrow compare to Tarsus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harrow (HROW) Competitors

HROW vs. AMRX, DFTX, INDV, MANE, and TARS

How does Harrow compare to Amneal Pharmaceuticals?

Does the media favor AMRX or HROW?

Which has higher earnings and valuation, AMRX or HROW?

Do insiders & institutionals have more ownership in AMRX or HROW?

Is AMRX or HROW more profitable?

Which has more volatility & risk, AMRX or HROW?

Do analysts rate AMRX or HROW?

Summary

How does Harrow compare to Definium Therapeutics?

Which has preferable earnings & valuation, DFTX or HROW?

Is DFTX or HROW more profitable?

Do institutionals and insiders hold more shares of DFTX or HROW?

Do analysts rate DFTX or HROW?

Does the media favor DFTX or HROW?

Which has more risk and volatility, DFTX or HROW?

Summary

How does Harrow compare to Indivior?

Which has higher earnings and valuation, HROW or INDV?

Is HROW or INDV more profitable?

Do analysts rate HROW or INDV?

Do insiders and institutionals believe in HROW or INDV?

Does the media prefer HROW or INDV?

Which has more volatility and risk, HROW or INDV?

Summary

How does Harrow compare to Veradermics?

Do insiders & institutionals believe in MANE or HROW?

Does the media refer more to MANE or HROW?

Do analysts rate MANE or HROW?

Which has preferable valuation and earnings, MANE or HROW?

Is MANE or HROW more profitable?

Summary

How does Harrow compare to Tarsus Pharmaceuticals?

Do analysts rate TARS or HROW?

Is TARS or HROW more profitable?

Which has more risk and volatility, TARS or HROW?

Does the media favor TARS or HROW?

Do institutionals and insiders believe in TARS or HROW?

Which has stronger earnings & valuation, TARS or HROW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools